The 5 best ASX 200 healthcare shares of financial year 2021

Which ASX healthcare giant bested the rest in the financial year just been?
The post The 5 best ASX 200 healthcare shares of financial year 2021 appeared first on The Motley Fool Australia. –

The S&P/ASX 200 Health Care index (ASX: XHJ) is where some of the most well-known Australian healthcare shares can be found. But only one can come out on top.  

Here are the 5 ASX 200 healthcare shares that bested the rest in the 2021 financial year.

5 best performing ASX 200 healthcare shares

Shareholders of these companies get ready to pat yourselves on the back.

Pro Medicus Limited (ASX: PME)

The Pro Medicus share price beat those of all other ASX 200 healthcare shares, gaining almost 122% in the 2021 financial year. Shares in the healthcare imaging software provider started the financial year trading for $26.46 and by its end, they were swapping hands for $58.72.

In January, Pro Medicus signed a 7-year contract with Intermountain Healthcare in Salt Lake City, the United States. Over the 4 days following the news, the Pro Medicus share price gained 38%. It then finished the financial year off strong by gaining 41% in its last 7 weeks.

The last time the market heard news from Pro Medicus was in May when the company’s subsidary signed a deal with The University of Vermont Health Network.

Healius Ltd (ASX: HLS)

The Healius share price ended the 2021 financial year 49% higher than when it began. Shares in the company lifted from $3.05 to $4.63 over the 12 months.

Healius is a healthcare company focused on pathology and imaging. It also has three up-and-coming business segments – dental, IVF, and day hospitals.

Healius started FY21 with a positive trading update, then released a healthy yearly earnings update in August, but chose not to pay a dividend.

In October 2020, it sold its medical centres business to BGH Capital for $483 million, which the company put towards an on-market buyback.

Cochlear Limited (ASX: COH)

The Cochlear share price gained 33% in the 12 months ended 30 June 2021. That saw its share price go from $188.93 to $251.67.

Cochlear is a manufacturer and distributor of hearing devices.

COVID-19 saw Cochlear started the financial year by reporting a drop in profits and settling a patent infringement case brought against it for $75 million.

Fortunately, despite the company staying extremely quiet thereafter, the Cochlear share price managed to recover over the 12-month period.

Sonic Healthcare Limited (ASX: SHL)

The Sonic share price made it be one of the ASX 200’s winning healthcare shares after gaining more than 26% over the 2021 financial year. On 30 June 2020, the Sonic share price was $30.43. Exactly 12 months later it was $38.40.

Sonic is a pathology provider with business in Australia, New Zealand, Europe, and the US.

Sonic stayed relatively quiet over the 2021 financial year. The last time the market heard news from Sonic was on 17 June. Then, it announced it had agreed to acquire Canberra Imaging Group for an unspecified cost.

Resmed CDI (ASX: RMD)

Last, but certainly not least, was the Resmed share price, which gained almost 20% over the 12 months ended 30 June 2021. Having started the 2021 financial year trading for $27.55, Resmed shares ended it swapping hands for $32.76.

Resmed works with respiratory medical devices. It focuses on the treatment of sleep apnoea.

The final day of the 2021 financial year saw the Resmed share price hit a new all-time high. It came despite silence from the company.

In fact, aside from several quarterly results, the market hasn’t heard any price-sensitive news from the ASX 200 healthcare company since July 2019.

Perhaps the boost was spurred by its major competitors’ decision to recall 3.5 million ventilation devices designed to treat sleep apnoea.

The post The 5 best ASX 200 healthcare shares of financial year 2021 appeared first on The Motley Fool Australia.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

*Returns as of May 24th 2021

More reading

Are these 2 high-flying ASX shares buys?

3 ASX 200 shares named as buys

Here’s how some of the top ASX SaaS shares performed in FY21

The Healius (ASX:HLS) share price hit a new 5-year high today
Leading broker names 3 blue chip ASX shares to buy

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended Cochlear Ltd. and Pro Medicus Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool Australia has recommended Cochlear Ltd., ResMed Inc., and Sonic Healthcare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!